Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors. (31st December 2022)
- Record Type:
- Journal Article
- Title:
- Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors. (31st December 2022)
- Main Title:
- Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors
- Authors:
- Yu, Jiang
Gou, Wenfeng
Shang, Haihua
Cui, Yating
Sun, Xiao
Luo, Lingling
Hou, Wenbin
Sun, Tiemin
Li, Yiliang - Abstract:
- Abstract: The poly (ADP-ribose) polymerase (PARP) inhibitors play a crucial role in cancer therapy. However, most approved PARP inhibitors cannot cross the blood-brain barrier, thus limiting their application in the central nervous system. Here, 55 benzodiazepines were designed and synthesised to screen brain penetrating PARP-1 inhibitors. All target compounds were evaluated for their PARP-1 inhibition activity, and compounds with better activity were selected for further assays in vitro . Among them, compounds H34, H42, H48, and H52 displayed acceptable inhibition effects on breast cancer cells. Also, computational prediction together with the permeability assays in vitro and in vivo proved that the benzodiazepine PARP-1 inhibitors we synthesised were brain permeable. Compound H52 exhibited a B/P ratio of 40 times higher than that of Rucaparib and would be selected to develop its potential use in neurodegenerative diseases. Our study provided potential lead compounds and design strategies for the development of brain penetrating PARP-1 inhibitors. HIGHLIGHTS: Structural fusion was used to screen brain penetrating PARP-1 inhibitors. 55 benzodiazepines were evaluated for their PARP-1 inhibition activity. Four compounds displayed acceptable inhibition effects on breast cancer cells. The benzodiazepine PARP-1 inhibitors were proved to be brain permeable. Graphical Abstract: UF0001
- Is Part Of:
- Journal of enzyme inhibition and medicinal chemistry. Volume 37:Number 1(2022)
- Journal:
- Journal of enzyme inhibition and medicinal chemistry
- Issue:
- Volume 37:Number 1(2022)
- Issue Display:
- Volume 37, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 37
- Issue:
- 1
- Issue Sort Value:
- 2022-0037-0001-0000
- Page Start:
- 952
- Page End:
- 972
- Publication Date:
- 2022-12-31
- Subjects:
- PARP-1 inhibitor -- cancer -- Rucaparib -- benzodiazepine -- CNS
Enzyme inhibitors -- Periodicals
Enzyme Inhibitors -- periodicals
Biochemistry -- periodicals
572.7 - Journal URLs:
- http://informahealthcare.com/loi/enz ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/14756366.2022.2053524 ↗
- Languages:
- English
- ISSNs:
- 1475-6366
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4979.465000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21163.xml